Abstract
BackgroundAspirin esterase (AE) activity can account for part of aspirin pharmacokinetics in the circulation, possibly being associated with the impairment of aspirin effectiveness as an inhibitor of platelet aggregation.AimsThe study was aimed at investigating the correlations of serum AE activity with cholinesterase (ChE) and metabolic variables in healthy subjects in comparison to subjects with type 2 diabetes mellitus (T2DM).MethodsIn cardiovascular disease-free T2DM subjects and healthy controls, the AE activity levels and/or the correlation patterns between AE and the other variables were analyzed.ResultsNeither AE nor ChE activities were higher in the subjects with T2DM. Serum AE activity strongly correlated with ChE as well as glucose/lipids variables such as total cholesterol and triglyceride in healthy subjects, while the correlations between AE and glucose/lipids variables were not present in T2DM subjects.ConclusionsThese data may reflect the pathophysiological changes between healthy and T2DM subjects. Our data may thus provide the basis for future studies to unravel the mechanisms.
Highlights
Aspirin esterase (AE) activity can account for part of aspirin pharmacokinetics in the circulation, possibly being associated with the impairment of aspirin effectiveness as an inhibitor of platelet aggregation
While AE was inversely correlated with high-density lipoprotein (HDL) cholesterol, this correlation did not reach a statistical significance level
A significant positive correlation between AE and ChE was observed in both groups of Type 2 diabetes mellitus (T2DM) and control, while the correlation level appeared somewhat high in the control group
Summary
Aspirin esterase (AE) activity can account for part of aspirin pharmacokinetics in the circulation, possibly being associated with the impairment of aspirin effectiveness as an inhibitor of platelet aggregation. Aspirin (acetylsalicylic acid), by virtue of its antipyretic, analgesic, anti-inflammatory and anti-platelet actions, is one of the most widely employed drugs in the prevention of cardiovascular disease. While its prophylactic use against athero-thrombosis is well-documented, the optimal dose that confers maximal anti-platelet action without increased risk of bleeding remains to be determined [1,2]. Serum aspirin esterase (AE) activity may account for part of aspirin pharmacokinetics and has been proposed as one source of variation in aspirin effectiveness [3]. Type 2 diabetes mellitus (T2DM) is a common health problem associated with cardiovascular disease, with an increasing incidence worldwide [4]. One study has recently reported an increased level of AE activity in patients with T2DM, and it has been suggested that this
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
